Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTACC: Therapy Escalation in Type 2 Diabetes
NCT03813316Phase 4Withdrawn
- Sponsor
- LMC Diabetes & Endocrinology
- Start
- May 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of sitagliptin and ertugliflozin in type 2 diabetes mellitus (T2DM), sponsored by LMC Diabetes & Endocrinology. Planned start May 2019; status: withdrawn.
02
Drugs
sitagliptinertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03813316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813316.